NASDAQ:CDNA - CareDx Stock Price, Forecast & News

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

CareDx Inc (NASDAQ:CDNA) issued its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.01 by $0.01. The business earned $33.80 million during the quarter, compared to the consensus estimate of $33.14 million. CareDx had a negative return on equity of 21.92% and a negative net margin of 18.25%. CareDx's quarterly revenue was up 59.4% on a year-over-year basis. View CareDx's Earnings History.

CareDx is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for CareDx.

CareDx issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $127-127.3 million, compared to the consensus revenue estimate of $125.4 million.

5 brokers have issued 1-year price targets for CareDx's stock. Their forecasts range from $35.00 to $63.00. On average, they anticipate CareDx's share price to reach $47.40 in the next year. This suggests a possible upside of 112.7% from the stock's current price. View Analyst Price Targets for CareDx.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

News headlines about CDNA stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CareDx earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for CareDx.

CareDx saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 3,890,000 shares, an increase of 5.7% from the November 28th total of 3,680,000 shares. Based on an average daily trading volume, of 768,400 shares, the short-interest ratio is currently 5.1 days. Approximately 9.5% of the shares of the company are sold short. View CareDx's Current Options Chain.

Some companies that are related to CareDx include Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Biocept (BIOC).

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include EXACT Sciences (EXAS), Aduro BioTech (ADRO), Alibaba Group (BABA), Advanced Micro Devices (AMD), Roku (ROKU), Tandem Diabetes Care (TNDM), Square (SQ), Micron Technology (MU), NVIDIA (NVDA) and AbbVie (ABBV).

CareDx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.49%), Selz Capital LLC (0.19%), TIAA FSB (0.14%), Sanders Morris Harris LLC (0.10%) and Alpine Global Management LLC (0.03%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View Institutional Ownership Trends for CareDx.

CDNA stock was sold by a variety of institutional investors in the last quarter, including TIAA FSB. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Sasha King and William A Hagstrom. View Insider Buying and Selling for CareDx.

CDNA stock was acquired by a variety of institutional investors in the last quarter, including Selz Capital LLC, Sanders Morris Harris LLC, Peregrine Capital Management LLC and Alpine Global Management LLC. View Insider Buying and Selling for CareDx.

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDNA stock can currently be purchased for approximately $22.29.

CareDx has a market capitalization of $945.90 million and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.View Additional Information About CareDx.

The official website for CareDx is http://www.caredxinc.com/.

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]